News
-
MAP Pharmaceuticals has appointed W. James O’Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O’Shea held a number of positions in operations and commercialization and… Read more . . .
-
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .
-
Applications due by January 31, 2012. Details of the award and submission information are avaiable on this document. The application form is available here. Applicants must work in academia or small and medium enterprises (SMEs)… Read more . . .
-
According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said,… Read more . . .
-
Fleming Pharmaceuticals says that it sold the rights to its Ocean brand saline nasal products, along with three other products, to Valeant, which will distribute the product through Valeant Pharmaceuticals North America LLC. Ocean nasal… Read more . . .
-
California pharmaceutical company Inverseon has announced that it will redirect its development program for INV102, an inverse beta agonist, to focus on smoking cessation and COPD rather than asthma, although it is continuing to seek… Read more . . .
-
According to an article published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, only about a third of asthma patients not using an inhaled corticosteroid (ICS) and 17% of… Read more . . .
-
An unnamed angel investment group is providing up to $3.5 million dollars to St. Renatus for Phase 3 clinical trials of its nasal mist dental anesthesia. St. Renatus announced in March 2011 that it had… Read more . . .
-
Mumbai-based pharmaceutical and biotechnology company Wockhardt says that it will launch its generic version of GSK’s Flonase fluticasone nasal spray in the US immediately after having received approval from the US FDA. The company will… Read more . . .
-
GlaxoSmithKline and Theravance have announced the completion of Phase 3 studies of their Relovair fluticasone furoate/vilanterol DPI for COPD. One Phase 3 study for the treatment of asthma remains to be completed. Despite the fact… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan